Tirzepatide injected into a vein: why the licensed route matters

What the SURMOUNT trials actually tested, and why route of administration is non-negotiable

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across several tirzepatide doses. Every participant received the drug as a subcutaneous injection once weekly. That is not a minor procedural detail; it is the method on which all the efficacy and safety data rests. At the highest dose, participants achieved average body-weight reductions of around 20–21% over 72 weeks. Those results are inseparable from subcutaneous delivery, because the route governs the rate at which tirzepatide enters the bloodstream.

Subcutaneous tissue acts as a depot. The drug disperses slowly into capillaries over hours, keeping plasma concentrations within the range the prescriber is managing. Push the same dose directly into a vein and the absorption curve collapses into a spike. None of that scenario was tested; none of the safety margins the SURMOUNT programme established would apply. The full guide to tirzepatide injections explains what subcutaneous administration looks like in practice.

Eli Lilly's SmPC, published on the electronic Medicines Compendium, states clearly that Mounjaro is for subcutaneous use only. This is a regulatory instruction, not a preference.

How to tell you are in the right layer of tissue, and why the KwikPen makes it easier

Concern about accidentally hitting a vein is understandable, especially for first-time injectors. The reassuring reality is that the recommended sites (the soft tissue of the abdomen, the outer thigh and the upper arm) contain very little vascular structure near the surface. A standard subcutaneous technique means pinching the skin, inserting the needle at a 90-degree angle and releasing the pinch before pressing the plunger. The Mounjaro KwikPen handles the needle depth automatically, which removes most of the variables.

Signs that a needle may have nicked a blood vessel include a small amount of blood at the injection site after withdrawing, or blood entering the needle cap before injection. Neither is necessarily dangerous, but both are reasons to remove the needle, apply gentle pressure and start again at a different spot. Detailed step-by-step guidance on technique is on the how-to-inject-tirzepatide page. The Mounjaro Patient Information Leaflet also covers this; your prescriber should be your first call if you are unsure.

One practical habit: keep the pen in the fridge door between uses so it is easy to find on injection day and stays at the correct storage temperature. Allowing it to reach room temperature for around 30 minutes before injecting makes the process more comfortable.

Intramuscular injection: a different but related risk

Some people who are anxious about intravenous injection ask whether intramuscular delivery is similarly risky. It is a distinct concern and the answer is the same: Mounjaro is not licensed for intramuscular use either. Muscle tissue is more vascular than subcutaneous fat, and the absorption rate from muscle differs from the subcutaneous profile. The prescriber's dose, the titration schedule and the tolerability guidance in the leaflet all assume subcutaneous delivery. A fuller explanation of what happens when an injection reaches muscle tissue rather than fat is on the injected-into-muscle guidance page.

If you are finding consistent technique difficult, the issue is usually the site or the way the skin is being handled rather than anything inherent to the pen. The Mounjaro KwikPen guide covers common technique questions, and our clinical team is available seven days a week for aftercare queries.

Starting treatment the right way: eligibility and what the process involves

Getting the injection technique right begins well before the first dose. In the UK, tirzepatide (sold as Mounjaro) is a prescription-only medicine for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes or dyslipidaemia. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber reviews each person's full medical picture before any prescription is issued, and that review happens again before every repeat.

Understanding the cost of private treatment is a reasonable part of the decision; you can read about how UK Mounjaro pricing has changed for context on what the market currently looks like. The Mounjaro overview page gives a broader picture of the medicine and what to expect. If you are thinking about starting, the right first step is a clinical consultation rather than sourcing a pen independently. Mounjaro is dispensed through a free consultation with our prescribers, who review every application the same day it is submitted. Check your eligibility there.